# Biotech Daily Digest ‚Äî 2025-09-24

**46 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 5 items
- Endpoints News: 11 items
- Fierce Biotech: 4 items
- MHRA ‚Äì News: 1 item
- arXiv q-bio: 25 items


## Eli Lilly Press Releases

- **[Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk](https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-verve-therapeutics-advance-one-time)**  
  _Fri, 25 Jul 2025 08:49:00 -0400_  
  INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of¬†Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston -based clinical-stage company developing genetic medicines for cardiovascular disease.

- **[Lilly confirms date and conference call for second-quarter 2025 financial results announcement](https://investor.lilly.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-second-quarter-2025)**  
  _Thu, 24 Jul 2025 10:00:00 -0400_  
  INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial

- **[Lilly and Verve announce expiration of Verve tender offer](https://investor.lilly.com/news-releases/news-release-details/lilly-and-verve-announce-expiration-verve-tender-offer)**  
  _Thu, 24 Jul 2025 08:00:00 -0400_  
  INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for (i) $10.50 per Share, net to the

- **[Lilly declares third-quarter 2025 dividend](https://investor.lilly.com/news-releases/news-release-details/lilly-declares-third-quarter-2025-dividend)**  
  _Mon, 23 Jun 2025 11:37:00 -0400_  
  INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025 , to shareholders of record at the close of

- **[Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference](https://investor.lilly.com/news-releases/news-release-details/lilly-participate-goldman-sachs-46th-annual-global-health-care)**  
  _Mon, 02 Jun 2025 10:00:00 -0400_  
  INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46 th Annual Global Health Care Conference on June 10, 2025 . Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m.,


## Endpoints News

- **[Hengrui, Glenmark ink ADC deal; Rome Therapeutics to seek 'strategic options'](https://endpoints.news/hengrui-glenmark-ink-adc-deal-rome-therapeutics-to-seek-strategic-options/)**  
  _Wed, 24 Sep 2025 14:30:23 +0000_  
  Plus, news about Manas AI, Dewpoint Therapeutics, Cyclerion Therapeutics, Monopar Therapeutics and Eupraxia:

 üá®üá≥ Hengrui hands Glenmark select licensing rights to its ADC: In a deal worth up to $1.1 billion ...

- **[Acadia discards nasal Prader-Willi drug after Phase 3 washout](https://endpoints.news/acadia-discards-nasal-prader-willi-drug-after-phase-3-washout/)**  
  _Wed, 24 Sep 2025 13:51:34 +0000_  
  Acadia Pharmaceuticals said Wednesday that its intranasal therapy for the genetic condition Prader-Willi syndrome has failed in a late-stage trial.

 "Given these results, we do not intend to investigate intranasal carbetocin any further," R&D chief ...

- **[Harmony Biosciences' cannabidiol drug fails Phase 3 trial in fragile X](https://endpoints.news/harmony-biosciences-cannabidiol-drug-fails-phase-3-trial-in-fragile-x/)**  
  _Wed, 24 Sep 2025 13:31:24 +0000_  
  Harmony Biosciences said its experimental drug ZYN002, a synthetic cannabidiol gel, failed a Phase 3 study in people with fragile X syndrome, which affects a small subset of people with autism ...

- **[RA and Forbion back Sparrow's $95M Series B for type 2 diabetes drug](https://endpoints.news/ra-and-forbion-back-sparrows-95m-series-b-for-type-2-diabetes-drug/)**  
  _Wed, 24 Sep 2025 12:30:41 +0000_  
  An Oregon biotech looking to treat type 2 diabetes patients with elevated cortisol has just secured new money from two of biotech's most prolific investors this year.

 RA Capital and Forbion have joined OrbiMed, RiverVest ...

- **[With successful trial, uniQure eyes 2026 launch for Huntington‚Äôs gene therapy](https://endpoints.news/uniqure-unwraps-phase-1-2-gene-therapy-data-for-huntingtons-disease/)**  
  _Wed, 24 Sep 2025 11:26:50 +0000_  
  UniQure said Wednesday that a high dose of its experimental gene therapy AMT-130 for Huntington‚Äôs disease hit the primary endpoint in a Phase 1/2 trial, and it‚Äôs now targeting an FDA submission early next year ...

- **[Biogen gets ‚Äòunexpected‚Äô CRL for high-dose Spinraza, will submit more technical data](https://endpoints.news/biogen-gets-unexpected-crl-for-high-dose-spinraza-will-submit-more-technical-data/)**  
  _Wed, 24 Sep 2025 11:08:55 +0000_  
  The FDA handed Biogen a complete response letter for a high-dose version of its spinal muscular atrophy treatment Spinraza over the need for additional chemistry, manufacturing and control data.

 The agency requested more technical information ...

- **[Gates, Clinton orgs team up with Indian manufacturers to make $40 generic of Gilead's twice-yearly PrEP drug](https://endpoints.news/gates-clinton-orgs-team-up-with-indian-manufacturers-to-make-40-generic-of-gileads-twice-yearly-prep-drug/)**  
  _Wed, 24 Sep 2025 11:00:26 +0000_  
  A landmark twice-yearly HIV prevention tool could be available for $40 per person per year in 120 low- and middle-income countries by 2027, major global foundations announced on Wednesday.

 The Gates Foundation said it will ...

- **[Aera Therapeutics jumps into in vivo CAR-T race with trial planned for 2026](https://endpoints.news/aera-therapeutics-jumps-into-in-vivo-car-t-race-with-trial-planned-for-2026/)**  
  _Tue, 23 Sep 2025 18:00:33 +0000_  
  Aera Therapeutics is the latest company hoping that a simple infusion can reprogram the immune system to wipe out errant cells responsible for autoimmune disease. It's planning on testing the

- **[Lilly sets aside $6.5B for new Texas site to make its obesity pill](https://endpoints.news/lilly-sets-aside-6-5b-for-new-texas-site-to-make-its-obesity-pill/)**  
  _Tue, 23 Sep 2025 17:00:55 +0000_  
  Eli Lilly on Tuesday announced plans for its second out of four new manufacturing builds in the US ‚Äî this time a $6.5 billion factory in Houston to house production of its oral GLP-1 drug orforglipron ...

- **[Neurocrine details Phase 2 results for depression drug](https://endpoints.news/neurocrine-details-phase-2-results-for-depression-drug/)**  
  _Tue, 23 Sep 2025 15:24:29 +0000_  
  Neurocrine Biosciences shared detailed results that showed its pill for major depressive disorder could potentially compete with Johnson & Johnson's Spravato, though the low dose of the drug performed better than the high one.  ...

- **[Bristol Myers said its next-gen multiple myeloma drug cut rates of detectable cancer. Will it get FDA approval?](https://endpoints.news/bristol-myers-said-its-next-gen-multiple-myeloma-drug-cut-rates-of-detectable-cancer-will-it-get-fda-approval/)**  
  _Tue, 23 Sep 2025 15:16:15 +0000_  
  Bristol Myers Squibb said a regimen that includes its experimental drug iberdomide led to no detectable cancer cells in a greater proportion of multiple myeloma patients than those who received standard treatments in a pivotal ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/harmonys-pivotal-fragile-x-trial-flops-high-placebo-response-creates-discord" hreflang="en">Harmony's pivotal Fragile X trial flops as high placebo response creates discord</a>](https://www.fiercebiotech.com/biotech/harmonys-pivotal-fragile-x-trial-flops-high-placebo-response-creates-discord)**  
  _Sep 24, 2025 9:20am_  
  Harmony Biosciences‚Äô $60 million bet on a once-failed Fragile X candidate has gone off the rails. Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a registrational trial of the synthetic cannabidiol missed its primary endpoint.

- **[<a href="https://www.fiercebiotech.com/biotech/uniqure-hopes-launch-1st-huntingtons-gene-therapy-next-year-following-phase-12-success" hreflang="en">uniQure hopes to launch 1st Huntington's gene therapy next year following phase 1/2 success </a>](https://www.fiercebiotech.com/biotech/uniqure-hopes-launch-1st-huntingtons-gene-therapy-next-year-following-phase-12-success)**  
  _Sep 24, 2025 8:39am_  
  UniQure has set its sights on submitting its Huntington‚Äôs disease gene therapy for approval next year after the asset was shown to slow progression of the neurodegenerative condition by 75% in a phase 1/2 trial

- **[<a href="https://www.fiercebiotech.com/medtech/medtronic-doubles-size-its-london-center-ai-and-robotic-surgery" hreflang="en">Medtronic doubles the size of its London center for AI and robotic surgery</a>](https://www.fiercebiotech.com/medtech/medtronic-doubles-size-its-london-center-ai-and-robotic-surgery)**  
  _Sep 23, 2025 1:46pm_  
  Located within the ‚ÄúSilicon Roundabout‚Äù area also known as East London Tech City, the R&D office is set to grow in square footage to 25,000 and maintain more than 200 employees.

- **[<a href="https://www.fiercebiotech.com/biotech/wall-street-spotlight-nyse-honors-years-fierce-15-winners" hreflang="en">Wall Street spotlight: NYSE honors this year's Fierce 15 winners</a>](https://www.fiercebiotech.com/biotech/wall-street-spotlight-nyse-honors-years-fierce-15-winners)**  
  _Sep 23, 2025 10:17am_  
  The New York Stock Exchange helped ring in this year‚Äôs Fierce 15 by honoring the winners on the trading floor Monday morning.


## MHRA ‚Äì News

- **[Paracetamol and pregnancy - reminder that taking paracetamol during pregnancy remains safe](https://www.gov.uk/drug-safety-update/paracetamol-and-pregnancy-reminder-that-taking-paracetamol-during-pregnancy-remains-safe)**  
  _2025-09-23T16:41:18Z_  
  Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at the lowest dose and for the shortest duration. It also acts as an antipyretic and is therefore‚Ä¶


## arXiv q-bio

- **[Securing the Language of Life: Inheritable Watermarks from DNA Language Models to Proteins](https://arxiv.org/abs/2509.18207)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18207v1 Announce Type: new 
Abstract: DNA language models have revolutionized our ability to understand and design DNA sequences--the fundamental language of life--with unprecedented precision, enabling transformative applications in therapeutics, synthetic biology, and gene editing. However, this capabilit‚Ä¶

- **[Stochastic Dynamics of Urban Predator-Prey Systems: Integrating Human Disturbance and Functional Responses](https://arxiv.org/abs/2509.18217)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18217v1 Announce Type: new 
Abstract: Urban ecosystems exhibit complex predator-prey dynamics increasingly disrupted by anthropogenic disturbances (e.g., noise, habitat fragmentation). Classical Lotka-Volterra (LV) models fail to capture these human-induced stressors, and integrated frameworks incorporating‚Ä¶

- **[Virtual Cells: From Conceptual Frameworks to Biomedical Applications](https://arxiv.org/abs/2509.18220)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18220v1 Announce Type: new 
Abstract: The challenge of translating vast, multimodal biological data into predictive and mechanistic understanding of cellular function is a central theme in modern biology. Virtual cells, or digital cellular twins, have emerged as a critical paradigm to meet this challenge by‚Ä¶

- **[Rank Ordering of Species Sensitivities to Chemicals: Discrepancies between Behavioral and Lethal Responses in Freshwater and Marine Invertebrates](https://arxiv.org/abs/2509.18225)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18225v1 Announce Type: new 
Abstract: Locomotor behavioural responses are increasingly recognized as sensitive and ecologically relevant indicators for assessing aquatic organism exposure to contaminants. They often occur at concentrations lower than those causing physiological damage, yet their consequence‚Ä¶

- **[Predicted decline in common bird and butterfly species despite conservation policies in Europe](https://arxiv.org/abs/2509.18227)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18227v1 Announce Type: new 
Abstract: In response to increasing threats to biodiversity, conservation objectives have been set at national and international level, with the aim of halting biodiversity decline by reducing direct anthropogenic pressures on species. However, the potential effects of conservati‚Ä¶

- **[Forest tree species classification and entropy-derived uncertainty mapping using extreme gradient boosting and Sentinel-1/2 data](https://arxiv.org/abs/2509.18228)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18228v1 Announce Type: new 
Abstract: We present a new 10-meter map of dominant tree species in Swedish forests accompanied by pixel-level uncertainty estimates. The tree species classification is based on spatiotemporal metrics derived from Sentinel-1 and Sentinel-2 satellite data, combined with field obse‚Ä¶

- **[Dynamical Modeling of Behaviorally Relevant Spatiotemporal Patterns in Neural Imaging Data](https://arxiv.org/abs/2509.18507)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18507v1 Announce Type: new 
Abstract: High-dimensional imaging of neural activity, such as widefield calcium and functional ultrasound imaging, provide a rich source of information for understanding the relationship between brain activity and behavior. Accurately modeling neural dynamics in these modalities‚Ä¶

- **[From Noise to Insight: Visualizing Neural Dynamics with Segmented SNR Topographies for Improved EEG-BCI Performance](https://arxiv.org/abs/2509.18599)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18599v1 Announce Type: new 
Abstract: Electroencephalography (EEG)-based wearable brain-computer interfaces (BCIs) face challenges due to low signal-to-noise ratio (SNR) and non-stationary neural activity. We introduce in this manuscript a mathematically rigorous framework that combines data-driven noise in‚Ä¶

- **[A Novel Mathematical Model of Protein Interactions from the Perspective of Electron Delocalization](https://arxiv.org/abs/2509.18882)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18882v1 Announce Type: new 
Abstract: Proteins are the workhorse molecules of the cell and perform their biological functions by binding to other molecules through physical contact. Protein function is then regulated through coupling of bindings on the protein (allosteric regulation). Just as the genetic co‚Ä¶

- **[Exploring aperiodic, complexity and entropic brain changes during non-ordinary states of consciousness](https://arxiv.org/abs/2509.19254)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.19254v1 Announce Type: new 
Abstract: Non-ordinary states of consciousness (NOC) provide an opportunity to experience highly intense, unique, and perceptually rich subjective states. The neural mechanisms supporting these experiences remain poorly understood. This study examined brain activity associated wi‚Ä¶

- **[Biochemical Network Motifs Under Periodic Forcing: A Selective Catalogue of Transfer Functions and Frequency Response Properties](https://arxiv.org/abs/2509.19290)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.19290v1 Announce Type: new 
Abstract: Understanding the function of network motifs in an attempt to gain insight into how their combinations create larger reaction networks that drive cellular functions, has been a longstanding pursuit of systems biology. One specific objective within this pursuit is unders‚Ä¶

- **[A deep reinforcement learning platform for antibiotic discovery](https://arxiv.org/abs/2509.18153)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18153v1 Announce Type: cross 
Abstract: Antimicrobial resistance (AMR) is projected to cause up to 10 million deaths annually by 2050, underscoring the urgent need for new antibiotics. Here we present ApexAmphion, a deep-learning framework for de novo design of antibiotics that couples a 6.4-billion-paramet‚Ä¶

- **[Explicit Path CGR: Maintaining Sequence Fidelity in Geometric Representations](https://arxiv.org/abs/2509.18408)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18408v1 Announce Type: cross 
Abstract: We present a novel information-preserving Chaos Game Representation (CGR) method, also called Reverse-CGR (R-CGR), for biological sequence analysis that addresses the fundamental limitation of traditional CGR approaches - the loss of sequence information during geomet‚Ä¶

- **[Probabilistic Geometric Principal Component Analysis with application to neural data](https://arxiv.org/abs/2509.18469)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18469v1 Announce Type: cross 
Abstract: Dimensionality reduction is critical across various domains of science including neuroscience. Probabilistic Principal Component Analysis (PPCA) is a prominent dimensionality reduction method that provides a probabilistic approach unlike the deterministic approach of‚Ä¶

- **[SimpleFold: Folding Proteins is Simpler than You Think](https://arxiv.org/abs/2509.18480)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18480v1 Announce Type: cross 
Abstract: Protein folding models have achieved groundbreaking results typically via a combination of integrating domain knowledge into the architectural blocks and training pipelines. Nonetheless, given the success of generative models across different but related problems, it‚Ä¶

- **[Reverse-Complement Consistency for DNA Language Models](https://arxiv.org/abs/2509.18529)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18529v1 Announce Type: cross 
Abstract: A fundamental property of DNA is that the reverse complement (RC) of a sequence often carries identical biological meaning. However, state-of-the-art DNA language models frequently fail to capture this symmetry, producing inconsistent predictions for a sequence and it‚Ä¶

- **[Bayesian Calibration and Model Assessment of Cell Migration Dynamics with Surrogate Model Integration](https://arxiv.org/abs/2509.18998)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.18998v1 Announce Type: cross 
Abstract: Computational models provide crucial insights into complex biological processes such as cancer evolution, but their mechanistic nature often makes them nonlinear and parameter-rich, complicating calibration. We systematically evaluate parameter probability distributio‚Ä¶

- **[A decentralized future for the open-science databases](https://arxiv.org/abs/2509.19206)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.19206v1 Announce Type: cross 
Abstract: Continuous and reliable access to curated biological data repositories is indispensable for accelerating rigorous scientific inquiry and fostering reproducible research. Centralized repositories, though widely used, are vulnerable to single points of failure arising f‚Ä¶

- **[Multi-Scale Graph Theoretical Analysis of Resting-State fMRI for Classification of Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls](https://arxiv.org/abs/2409.04072)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2409.04072v3 Announce Type: replace 
Abstract: Alzheimer's disease (AD) is a neurodegenerative disorder marked by memory loss and cognitive decline, making early detection vital for timely intervention. However, early diagnosis is challenging due to the heterogeneous presentation of symptoms. Resting-state funct‚Ä¶

- **[Biology-Instructions: A Dataset and Benchmark for Multi-Omics Sequence Understanding Capability of Large Language Models](https://arxiv.org/abs/2412.19191)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2412.19191v2 Announce Type: replace 
Abstract: Large language models (LLMs) have shown remarkable capabilities in general domains, but their application to multi-omics biology remains underexplored. To address this gap, we introduce Biology-Instructions, the first large-scale instruction-tuning dataset for multi‚Ä¶

- **[THFlow: A Temporally Hierarchical Flow Matching Framework for 3D Peptide Design](https://arxiv.org/abs/2502.15855)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2502.15855v2 Announce Type: replace 
Abstract: Deep generative models provide a promising approach to de novo 3D peptide design. Most of them jointly model the distributions of peptide's position, orientation, and conformation, attempting to simultaneously converge to the target pocket. However, in the early sta‚Ä¶

- **[XDIP: A Curated X-ray Absorption Spectrum Dataset for Iron-Containing Proteins](https://arxiv.org/abs/2504.18554)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2504.18554v2 Announce Type: replace 
Abstract: Earth-abundant iron is an essential metal in regulating the structure and function of proteins. This study presents the development of a comprehensive X-ray Absorption Spectroscopy (XAS) database focused on iron-containing proteins, addressing a critical gap in avai‚Ä¶

- **[Language Models Do Not Have Human-Like Working Memory](https://arxiv.org/abs/2505.10571)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2505.10571v3 Announce Type: replace 
Abstract: While Large Language Models (LLMs) exhibit remarkable reasoning abilities, we demonstrate that they lack a fundamental aspect of human cognition: working memory. Human working memory is an active cognitive system that enables not only the temporary storage of inform‚Ä¶

- **[Complexity-Informed Causal Modeling of Neurodevelopmental Trajectories in Pediatric High-Grade Gliomas: Divergences from Neural Stem Cell Signatures](https://arxiv.org/abs/2508.13198)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2508.13198v2 Announce Type: replace 
Abstract: Pediatric high grade gliomas are lethal evolutionary disorders with stalled developmental trajectories and disrupted differentiation hierarchies. We integrate transcriptional and algorithmic network complexity based perturbation analysis to elucidate gene expression‚Ä¶

- **[CEP-IP: An Explainable Framework for Cell Subpopulation Identification in Single-cell Transcriptomics](https://arxiv.org/abs/2509.12073)**  
  _Wed, 24 Sep 2025 00:00:00 -0400_  
  arXiv:2509.12073v2 Announce Type: replace 
Abstract: TRPM4 is overexpressed in prostate cancer (PCa) associated with metastasis or recurrence. There is paucity of information pertaining to TRPM4 characterization and functions at single-cell level in PCa. This study introduces the CEP-IP framework, a novel explainable‚Ä¶
